Gothenburg, Sweden, September 16 2016 – Immunicum AB (publ), a biopharmaceutical company pursuing to develop sophisticated, safe and efficient therapeutic cancer treatments with powerful and long lasting immune responses, today announced continued data improvement from the follow-up phase of a phase I/II-trial in eleven patients with metastatic kidney cancer that started in February 2012. Five patients are still alive and the data show an ongoing, more than doubled median overall survival for the entire patient group and an ongoing right now more than tripled median overall survival for patients with poor prognosis compared to published historical data for newly diagnosed patients who received standard treatment.
Immunicum initiated a phase I/II study in patients with metastasized renal cell cancer in February 2012. The patients were treated with two intratumoral doses of INTUVAX before the primary tumor was surgically removed. Five (5) of the eleven (11) evaluable patients are still alive. Median overall survival for the entire patient population currently stands at about 40 months versus expected 15.2 months (historical data on newly diagnosed patients with metastatic renal cancer treated with the tyrosine kinase inhibitor Sutent/sunitinib). For the group with high-risk prognosis (6 patients), the median overall survival is currently at about 32 months versus expected nine (9) months and for patients with intermediate prognosis (5 patients), the median overall survival is currently at about 45 months versus expected 26 months. The final median overall survival has not yet been reached for any of the three patient groups.
The purpose of the phase I/II study was to document the safety profile and immunological effects, as well as to follow the survival of patients with metastatic renal cell cancer after two INTUVAX treatments.
For further information, please contact:
Jamal El-Mosleh, CEO, Immunicum
Phone: +46 (0) 31 41 50 52
The Company’s Certified Adviser is Redeye AB
Phone: +46 (0) 8 545 013 31. www.redeye.se
INTUVAX is a cancer immune primer, developed for the treatment of solid tumors. Its active ingredient is activated white blood cells, so called dendritic cells, derived from healthy blood donors. Intratumoral injection of these cells is expected to lead to an inflammatory response which in turn leads to tumor-specific activation of the patient’s cytotoxic T lymphocytes.
About Immunicum AB (publ)
Immunicum AB (publ) is working to develop and advance cancer immune primers for the treatment of tumor diseases. A clinical phase II trial for the Company’s most advanced product – INTUVAX® against kidney cancer – has been initiated. The project portfolio contains additional clinical phase I/II studies in liver cancer and in gastrointestinal stromal tumors (GIST).
For more information, please visit www.immunicum.com
The information in this press release is disclosed pursuant to the EU Market Abuse Regulation. The information was released for public disclosure through the agency of the company’s contact person on September 16, 2016 at 10.50 CET.